

80444_Auto_Edited.docx

Name of Journal: *World Journal of Hepatology*

Manuscript NO: 80444

Manuscript Type: REVIEW

COVID-19 and Liver Injury: Pathophysiology, risk factors, outcome and management in special populations

COVID-19 and Liver Injury

Romina Roshanshad, Amirhossein Roshanshad, Reza Fereidooni, Mahnaz Hosseini-Bensenjan

Abstract

The coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is an ongoing health concern. In addition to affecting the respiratory system, COVID-19 can potentially damage other systems in the body, leading to extra-pulmonary manifestations. Hepatic manifestations are among the common consequences of COVID-19. Although the precise mechanism of liver injury is still questionable, several mechanisms have been hypothesized, including direct viral effect, cytokine storm, hypoxic-ischemic injury, hypoxia-reperfusion injury, ferroptosis, and hepatotoxic medications. Risk factors of COVID-19-induced liver injury include severe COVID-19 infection, male gender, advanced age, obesity, and underlying diseases. The presentations of liver involvement comprise abnormalities in liver enzymes and radiologic findings, which can be utilized to predict the prognosis. Increased gamma-glutamyltransferase (GGT), aspartate aminotransferase (AST), and alanine aminotransferase (ALT) levels with hypoalbuminemia can indicate severe liver injury and anticipate the need for intensive care units (ICU) hospitalization. In imaging, a lower liver-to-spleen (L/S) ratio and liver CT attenuation may indicate a more severe illness. On top of that, chronic liver disease patients are at a higher risk for severe disease and death from COVID-19. Nonalcoholic fatty liver disease (NAFLD) had the highest risk of advanced COVID-19 disease and death, followed by metabolic-associated fatty liver disease (MAFLD) and cirrhosis. In addition to COVID-19-induced liver injury, the pandemic has also altered the epidemiology and pattern of some hepatic diseases, such as alcoholic liver disease and hepatitis B. Therefore, it warrants special vigilance and awareness by healthcare professionals to screen and treat COVID-19-associated liver injury accordingly.

Key Words: SARS-CoV-2; COVID-19; Liver injury; Chronic liver disease; Management; Liver transplant

Roshanshad R, Roshanshad A, Fereidooni R, Hosseini-Bensenjan M. COVID-19 and Liver Injury: Pathophysiology, risk factors, outcome and management in special populations . *World J Hepatol* 2023; In press

16

Core Tip: Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) can involve the liver and cause damage through different mechanisms. Liver injury can be diagnosed based on alterations in the liver function tests, which can also predict the disease severity and fatality. In patients without underlying liver disease, the disease course is typically mild and can be treated with supportive care. However, it requires additional awareness and appropriate therapy in patients with chronic liver diseases, including autoimmune hepatitis, viral hepatitis, liver cirrhosis, liver transplantation, and nonalcoholic fatty liver disease, which we have discussed in detail.

17

INTRODUCTION

The coronavirus disease 2019 (COVID-19) pandemic has tremendously influenced global public health since its emergence in December 2019. Despite the effectiveness of worldwide vaccinations, the disease is still a substantial threat^[1]. As of 6 January 2023, the World Health Organization (WHO) recorded over 657 million confirmed cases of COVID-19 and over 6.6 million deaths^[2].

COVID-19 was first recognized as a respiratory disease with variable manifestations, from asymptomatic and mild symptoms to acute respiratory distress syndrome and death. However, further investigations determined that COVID-19 can cause various extra-pulmonary manifestations and result in multi-organ dysfunction^[3]. Various theories have been suggested to explain how COVID-19 causes gastrointestinal (GI) system involvement. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) penetrates the host cells via angiotensin converting enzyme 2 (ACE2) receptors, which exist in different tissues, including the GI system. This may result in GI manifestations such as nausea, vomiting, diarrhea, anorexia, and hepatic manifestations^[4]. After the lungs, the liver is the second most frequent organ impacted

by COVID-19^[5]. COVID-19-induced liver damage may develop in patients regardless of the presence of underlying liver diseases; however, the likelihood of poorer outcomes is higher in patients with underlying chronic liver disease^[5, 6]. Chronic liver disease (CLD) constitutes a significant worldwide health burden. About 3% of COVID-19 patients have CLD, and this group has a higher risk of developing severe disease and death^[7]. Moreover, due to their use of immunosuppressive drugs and weakened immune systems, stringent monitoring is required^[8].

In this review, we aimed to comprehensively investigate different related aspects of liver injury in COVID-19. We discuss the pathophysiology, epidemiology, clinical manifestations, management, and outcomes of COVID-19 patients with liver injury. We also covered important topics like the interaction between COVID-19 and various types of liver disease, as well as unique considerations for particular populations with CLD and liver transplant (LT) recipients.

MECHANISMS AND PATHOPHYSIOLOGY OF LIVER INJURY IN COVID-19 PATIENTS

Although the exact mechanism of liver injury in COVID-19 is yet to be understood, several pathways have been proposed. The direct viral effect, drug hepatotoxicity, systematic inflammatory response (cytokine storm), decompensation of pre-existing liver disease, and hypoxic liver injury are among the suggested hypotheses^[9]. Figure 1 demonstrates the proposed mechanisms of liver injury in COVID-19.

Direct viral effect

Although almost none of the current histopathological reports has shown a typical hepatitis picture^[10], some evidence argues in favor of liver tropism and the direct effect of the virus on the liver. Firstly, the SARS-CoV-2 receptor, ACE2, is found on the surface of the hepatic Kupffer cells, hepatocytes, and cholangiocytes which helps the virus enter these cells and, as a result, makes the liver a potential target organ for the virus^[11-13]. Secondly, Wang *et al*^[14] discovered the SARS-CoV-2 spike structures in the cytoplasm of hepatocytes in two COVID-19 cases. The spatial presence of SARS-CoV-2

RNA and spike protein was also proved by previous studies in hepatic cells, which implies replication of the virus and direct infection of hepatic parenchyma^[11, 15]. Wanner *et al*^[11] discovered a lower viral load in the liver than in the lungs of one patient, suggesting this may be the reason we do not typically observe cytopathic changes (i.e., hepatitis pattern) in the liver of COVID-19 patients.

Systemic inflammatory response (cytokine storm)

In response to COVID-19 and in order to hinder viral replication and evoke the adaptive immune response, the innate immune system is activated^[16]. Severe cases of COVID-19 are associated with an exaggerated immune response indicated by high levels of c-reactive protein (CRP), pro-inflammatory T helper 17 (Th17) cells, and cytokines^[16, 17]. Cytokines in severe cases of COVID-19 include interleukins 2, 6, 7, 8, 10, and 1B and Tumor necrosis factor alpha (TNF- α)^[16-18]. Pathological studies have demonstrated non-specific inflammatory changes in the hepatocytes, including steatosis, lymphocyte infiltration, and Kupffer cell hyperplasia^[17]. This immune system dysregulation can result in multiple organ involvement, including the liver. The cytokine storm not only affects the liver by triggering the inflammatory response and recruiting macrophages; but also plays a role in further indirect damage by promoting thrombotic events, circulatory changes, and failure of other organs^[18].

Hypoxic-ischemic injury, hypoxia-reperfusion injury, and liver congestion

While shock as the result of the COVID-19 infection itself is not a common finding^[19], it is a common entity in intensive care units (ICU)^[20]. COVID-19 patients are susceptible to all types of shock (i.e., cardiogenic, septic, hypovolemic, and obstructive)^[19, 21, 22]. While shock reduces liver perfusion, respiratory failure can also produce hypoxic harm to the liver, even in the absence of ischemia^[20, 23]. On the other hand, COVID-19 is known to induce microangiopathy and thromboembolism that further compromises the liver blood supply^[24]. In the context of COVID-19, liver damage and coagulopathy are connected. Rise in transaminases have been shown to correlate with abnormal

coagulopathy ⁹ markers, such as prothrombin time, international normalized ratio, fibrinogen, D-dimer, fibrin/fibrinogen degradation products and platelet count^[25]. Different organ involvements in COVID-19, including cardiac, pulmonary, and vascular involvement, paired with the high metabolic activity of the liver, makes it a highly susceptible organ to hypoxic-ischemic damage^[26]. In the autopsy of COVID-19 patients, ischemic-type hepatic necrosis and lipid droplet accumulation (steatosis) have been found in histopathologic evaluations, both findings in favor of hypoxic-ischemic liver damage^[10, 27]. However, the hallmark of hypoxic hepatitis is a significant increase in liver enzymes, and the increase reported in the COVID-19 scenario is notably less^[28]. Hence some have hypothesized that hypoxia-reperfusion is another explanatory mechanism^[21]. ⁸ Hepatic congestion is caused by the stasis of blood within the liver parenchyma due to the compromise of hepatic venous drainage^[29]. Congestion of the hepatic sinusoids was estimated at 34.7% in a histopathologic study^[30]. Cardiac events resulting in right-sided heart failure, decompensation of heart failure, and pulmonary thromboembolism can contribute to liver congestion in COVID-19 patients^[21]. In a review by Kukla *et al*^[31], hepatic dysfunction was associated with mechanical ventilation, especially with high rates of positive end-expiratory pressure (PEEP). They hypothesized that high PEEP (18-20 cm H₂O) causes high right atrial pressure resulting in liver congestion in a mechanism similar to right-sided heart failure. In a hemodynamic study of COVID-19 patients, mechanical ventilation and PEEP were associated with left ventricular underfilling^[23].

Ferroptosis

²¹ Ferroptosis is a novel form of cell death, which is characterized by iron accumulation and lipid peroxidation^[32]. The oxidative stress caused by iron overload is an important trigger for liver injury as well as other vital organ damage^[33]. COVID-19 is believed to impact iron metabolism^[34]. In the condition of cytokine storm, interleukin-6 (IL-6) stimulates the production of hepcidin in the liver, which is an inhibitor of iron export and leads to iron sequestration inside cells^[35]. It is hypothesized that SARS-CoV-2 triggers the recognition of blood iron-binding molecules by receptors in many organs,

including the liver, thereby causing an influx of iron ions. The accumulated iron, along with agents like lipid and hydrogen peroxide, triggers the Fenton reaction, producing massive lipid reactive oxygen species that cause cell membrane damage^[36]. In conclusion, ferroptosis is a potentially important mechanism of organ damage in COVID-19; however, the extent of its role and whether treatments that inhibit ferroptosis can be helpful in preventing organ damage in COVID-19 remains to be determined^[35, 37].

Medications

Medication hepatotoxicity has strong evidence as the cause of liver injury ³ in the context of COVID-19^[38]. Owing to the novel nature of the COVID-19 infection and the lack of evidence-based guidelines, various medications have been used for treatment, many of which have potential hepatotoxic properties. These include antivirals (including remdesivir, lopinavir/ritonavir, Favipiravir), hydroxychloroquine, antibiotics (e.g., azithromycin), corticosteroids, tocilizumab, and antipyretics, specifically acetaminophen^[21, 38, 39]. Remdesivir has been associated with transient increases in liver enzymes in Gilead company trials in less than 5% of participants and was indicated to possibly be cytotoxic to human hepatocytes at clinically relevant exposures^[40, 41]. Consistently, liver injury in remdesivir-treated COVID-19 cases was mostly mild, according to published literature^[42-44]. Wang *et al*^[32] reported that 7% of a remdesivir-treated group developed grade 1-2 aspartate aminotransferase (AST) elevation compared to 12% in a placebo-controlled group, and 1% developed grade 1-2 alanine aminotransferase (ALT) elevation. Case reports have revealed that associate Favipiravir, another antiviral agent used to treat COVID-19, with liver injury^[45, 46]. However, a systematic review on the safety of Favipiravir in COVID-19 failed to prove the association between the drug and liver injury^[47]. The use of lopinavir/ritonavir has been linked to liver toxicity in multiple studies of COVID-19 patients^[38]. Serum aminotransferases increase in a large number of individuals using antiretroviral regimens containing ritonavir. Moderate to severe elevations in the serum aminotransferase levels are detected in up to 15% of patients treated with full dosages

of ritonavir^[48]. In the setting of COVID-19, Cai *et al*^[49] also found lopinavir/ritonavir to be associated with increased odds of liver injury. Yip *et al*^[50] showed that the use of lopinavir/ritonavir ± ribavirin + interferon beta was independently associated with elevated liver enzymes. The use of systemic corticosteroids is highly encouraged in COVID-19, especially in patients requiring oxygen supplement therapy^[51]. A cohort study in Hong Kong reported the independent association of corticosteroids with elevated AST/ALT^[50]. However, extensive data on the hepatotoxicity of corticosteroids is non-existent, and it's usually confined to case reports^[51]. Some have even proposed them to treat drug-induced liver injury^[52]. One potential way of corticosteroid-induced liver toxicity may be its role in inducing non-alcoholic steatohepatitis^[51]. Tocilizumab, a humanized recombinant monoclonal antibody, is used to combat systematic inflammatory response in COVID-19 because of its anti-IL-6 properties^[53]. Hepatotoxicity with transient, mild to moderate transaminase increase is its well-known side effect, but severe drug-induced liver injury is a rare event^[53, 54]. Hydroxychloroquine and chloroquine are the standard medications to treat malaria and had been explored as treatment options for COVID-19 due to their *in vitro* anti-SARS-CoV-2 properties^[55]. Liver injury associated with hydroxychloroquine is uncommon and limited to case reports^[56-58]. Azithromycin, a macrolide antibiotic, was also advocated for the treatment of COVID-19 owing to its cytokine-suppressing features, potentially preserving the epithelial cells and inhibiting lung fibrosis^[59]. Azithromycin is known to cause liver injury, with both hepatocellular and cholestatic patterns^[60, 61]. Ivermectin, an anti-parasite drug, was reported to be associated with one case of severe hepatitis; however, there is insufficient data to comment on the effects of ivermectin on the liver function of COVID-19 patients, and more research is needed to clarify this^[38, 62]. So far, there is no report in the literature about acetaminophen-associated hepatotoxicity in COVID-19 patients; this is likely because acetaminophen-induced hepatotoxicity is highly dose-dependent, and its safe dose is well-established^[63]. Additionally, it should be highlighted that, despite dosages used in

patients normally belonging within safe ranges, combination therapy with various hepatotoxic drugs may have a synergistic effect.

COVID-19 AND LIVER MANIFESTATIONS

COVID-19 is usually regarded as a respiratory disease; however, subsequent research revealed extra-pulmonary manifestations of COVID-19, including cardiovascular, gastrointestinal, renal, ocular, neurological, psychiatric, dermatological, and endocrinology symptoms^[64, 65]. GI manifestations of COVID-19 are among the most common extra-pulmonary manifestations, and they can emerge even before the appearance of respiratory symptoms. Also, they can be the sole manifestation in some COVID-19 patients^[66]. It seems ¹⁵ that patients with COVID-19 who experience GI symptoms have a higher risk of elevated liver enzymes and liver injury^[16, 67]. The prevalence of liver injury in COVID-19 patients ranges widely from 21.5% to 45.71%^[68]. This wide range is because of the specific characteristics of different populations and cut-off level discrepancies^[69]. Liver injury usually manifests as abnormalities in liver enzymes. In a meta-analysis by Yadav *et al*^[68], the prevalence of liver enzymes abnormalities among COVID-19 patients ranged from 37.2% to 76.3%. In another meta-analysis, an elevation in the liver enzymes was reported in about 25% of COVID-19 patients, and the prevalence of increased AST and ALT was 23.2% and 21.2%, respectively. Gamma-glutamyltransferase (GGT) was elevated in 15%, total bilirubin (TBIL) in 9.7%, and alkaline phosphatase (ALP) in 4% of the patients^[67]. Hence, close monitoring of liver enzymes in COVID-19 patients is essential for timely diagnosis of liver injury.

RISK FACTORS FOR LIVER INJURY AND PREDICTORS OF DISEASE SEVERITY

Certain risk factors can predispose patients to develop liver injury. Some laboratory findings, such as lymphopenia, elevated AST/ALT ratio, higher triglyceride, ESR, and CRP levels are linked to the development of liver injury in COVID-19 patients^[68, 70]. In addition, male gender, obesity, and advanced age are the risk factors for liver injury in

COVID-19 patients^[49]. The higher odds of COVID-19 induced liver injury among males may be due to the higher prevalence of existing risk factors, such as nonalcoholic fatty liver disease (NAFLD) and alcohol intake^[71, 72]. Previous studies have linked abnormalities in liver enzymes and liver injury to disease severity and mortality^[73]. The abnormalities in liver function tests (LFT) can be used to predict the outcome of the disease. In a study conducted by Cai *et al*^[49], the patients who had hepatocellular and mixed patterns of liver involvement were at higher risk of developing severe disease. A hepatocellular pattern was determined as an increase in aminotransferases (ALT/AST) levels higher than three times the upper limit of normal (ULN), while a mixed pattern was determined as an increase in aminotransferases greater than three times the ULN and ALP/GGT greater than twice the ULN.

Weber *et al*^[74] demonstrated the correspondence between abnormal baseline liver enzymes and disease progression in patients without underlying liver disease. Increased GGT, AST, and ALT levels with hypoalbuminemia upon admission predicted the severity of the illness and the requirement for ICU hospitalization. Other studies have confirmed the link between low albumin levels and the severity of COVID-19. Hypoalbuminemia in severely ill COVID-19 patients is likely due to a combination of impaired hepatic albumin production and dietary deficiencies.^[16, 75] Phipps *et al*^[73] revealed that higher levels of peak ALT and markers of inflammation, such as ferritin and IL-6, were strongly linked to progression to severe liver injury and a poorer outcome.

RADIOLOGIC FINDINGS OF THE LIVER IN COVID-19 PATIENTS

Some radiologic manifestations of liver damage have been reported in COVID-19 patients. On abdominal CT scans of COVID-19 patients, hepatic hypodensity and fat stranding around the gallbladder were observed^[76]. Some findings, such as a decrease in liver-to-spleen (L/S) attenuation ratio and liver CT attenuation, may be relevant to the severity of the disease^[77, 78]. Chen *et al*^[70] demonstrated that hepatic steatosis on CT scan was observed in 11.3% of COVID-19 cases, which enhanced the risk of hepatic

dysfunction. In addition, they mentioned that while a decrease in hepatic attenuation on a baseline CT scan is rampant, it is usually a temporary condition that improves on subsequent CT scans. The most prevalent findings of abdominal ultrasound of COVID-19 patients in ICU were hepatomegaly and biliary abnormalities, including common bile duct dilatation, gallbladder distention, and wall thickening^[79]. Also, it was shown that in patients with mildly increased liver enzymes, hepatic ultrasonography was often not significant. However, in patients with a substantial rise in liver enzymes, hepatic ultrasound may detect vascular abnormalities or cholestatic changes, which is tied to higher fatality rates^[80].

COVID-19 VACCINATION AND LIVER INJURY

With widespread vaccination against COVID-19, many reports of immune-mediated liver injury (ILI) associated with vaccination have emerged^[81-85]. Most cases develop a hepatocellular pattern of injury^[84]. The proposed hypothesis is that due to the similarity between S protein and liver specific proteins, the immune response elicited against the S protein, which is encoded by the vaccines, may cause autoimmune-like hepatitis^[86]. Histopathological evaluation of the patients with ILI demonstrated portal lymphoplasmacytic infiltration and interface hepatitis^[87]. The prognosis of immune-mediated vaccine-induced liver injury seems to be excellent with corticosteroid treatment, with only 4.3% death among patients who received steroids^[87].

Roy *et al*^[87] reviewed ILI following COVID-19 vaccinations. Most of the patients with ILI were female, with a mean age of 55.3 years. Moderna mRNA-1273 was the most common culprit for ILI following COVID-19 vaccinations, followed by Pfizer- BioNTech BNT162b2 mRNA and AstraZeneca ChAdOx1 nCoV-19 vaccine. Inactivated vaccines can also contribute to ILI; however, the reports are much more scarce than mRNA vaccines^[88]. The most common presentation of ILI was jaundice, which was present in 78.3% of the patients, and bilirubin, ALT, and ALP levels were elevated. There is a dispute over the diagnosis of ILI following vaccination. Physicians should consider the clinical symptoms, liver function tests, histopathological findings,

and chronological association between vaccine injection and presentations of the symptoms.

OUTCOME, MANAGEMENT, AND CONSIDERATIONS IN SPECIAL POPULATIONS

Liver involvement is a common finding in patients with COVID-19; however, it is frequently mild, transitory, and resolves without management^[73, 89]. Nevertheless, patients with underlying liver diseases, including hepatitis, cirrhosis, or LT recipients, are at higher risk of severe diseases. It is estimated that the probability of developing severe disease and death due to COVID-19 was 2.44 times greater in patients with CLD compared to those without underlying liver diseases [Odds ratio (OR) for severity= 2.44 (95%CI: 1.89, 3.16), OR for mortality= 2.35 (95%CI: 1.84, 3.00)]^[90]. Among different underlying liver diseases, NAFLD was associated with the highest odds of severe disease and death due to COVID-19, followed by metabolic-associated fatty liver disease (MAFLD) and cirrhosis^[90]. Severity and mortality rates after COVID-19 were not impacted by viral hepatitis significantly. Table 1 demonstrates the strength of the association between several major underlying liver diseases and the severity and mortality of COVID-19.

Autoimmune hepatitis

The most common presentations of COVID-19 in patients with autoimmune hepatitis (AIH) were respiratory (74%) and GI (26%) manifestations^[91]. However, AIH patients are more likely to present with GI manifestations than the general population (26% vs. 14%). The mortality rate and cause of death of the AIH group were not significantly different from the non-AIH CLD group. Age [OR per 10 years: 2.01 (95%CI: 1.07, 3.81)], Child-Pugh B [OR: 42.48 (95%CI: 4.41, 409.53)], and Child-Pugh C [OR: 69.30 (95%CI: 2.83, 1694.50)] cirrhosis were the determinants of mortality within AIH patients^[91].

AIH is an immune-mediated liver disease, which is mainly responsive to immunosuppressive therapy^[92]. Single corticosteroid therapy or in combination with azathioprine are the standard immunosuppressive treatments for AIH^[93]. Other drugs

used to treat AIH include mycophenolate mofetil (MMF), calcineurin inhibitors, and TNF- α blockers^[93]. The immunosuppression status following the use of these drugs enhances the risk of bacterial and viral infections in these patients^[93] and might theoretically lead to a more severe COVID-19. Therefore, it is crucial to closely monitor the immunosuppressed AIH patients affected by COVID-19. In patients with simultaneous AIH and COVID-19, immunosuppressive therapy should be given after evaluating the risks and benefits. It is suggested that immunosuppressive therapy can be lifesaving in severe AIH patients^[94]. Thus, it is not wise to discontinue the treatment as it might predispose the patients to a higher risk of relapse. In conclusion, empirical reduction in the doses of immunosuppressive drugs in these patients during the course of COVID-19 can be potentially harmful^[95]; however, the immunosuppression therapy can be delayed until the COVID-19 PCR test becomes negative in milder forms of AIH^[94].

In addition to the impacts of COVID-19 on the management of AIH during the pandemic, SARS-CoV-2 has been proposed as a possible trigger for AIH. In a study by Kabaçam *et al*^[94], COVID-19 patients were diagnosed with AIH after presenting with high serum aminotransferase and IgG levels. It should be noted that there is an AIH-like liver injury that might occur following COVID-19 vaccination. The laboratory findings are similar to AIH in these cases, and there is a good response to corticosteroids in these patients^[96, 97].

Viral hepatitis B

The prevalence of HBV in patients with COVID-19 ranges from 0.1% in a study in the United States to 12.2% in China^[98, 99]. Interestingly, these prevalence rates were not significantly higher than the general population. Furthermore, there is no well-established association between HBV infection and severe COVID-19 disease^[99-102]. Surprisingly, some studies reported a milder course of COVID-19 in patients with HBV^[99, 101, 103, 104]. One hypothesis is that patients with HBV might experience a state of “immune exhaustion”, which can be responsible for a lower chance of developing cytokine storm^[105].

The treatment of COVID-19 with corticosteroids and other immunosuppressive drugs, including tocilizumab, may lead to the reactivation of HBV infection in these patients. Therefore, screening for HBV in COVID-19 patients with elevated liver enzymes in endemic HBV populations is highly recommended^[106]. It has been found that ICU admission, hospital admission, and organ failure in COVID-19 patients with HBV were higher compared to others^[107]. Several treatments were recommended for COVID-19 infection in HBV patients. A suggested method is drug repositioning, which means that the antiviral HBV drugs could also be used to treat COVID-19 infection^[107, 108]. In COVID-19 HBsAg-positive patients who are not receiving anti-HBV medication, continuous corticosteroid or immunosuppressant drug use necessitates prophylaxis with tenofovir disoproxil fumarate, tenofovir alafenamide, and entecavir to reduce the likelihood of reactivation and liver failure ^[70].

Table 1 The Association of different underlying liver diseases with Clinical Outcomes of COVID-19

Underlying liver disease/condition

Findings

Autoimmune hepatitis

AIH vs. other CLDs: No significant differences in hospital admission (76% vs. 85%; $P = 0.06$), ICU admission (29% vs. 23%; $P = 0.240$), and mortality (23% vs. 20%; $P = 0.643$) rates

AIH vs. non-CLDs: Higher hospitalization rate, but similar rate for other outcomes

Severity of AIH associates with COVID-19 mortality, as follows:

Age OR per 10 years: 2.01 (95%CI: 1.07, 3.81)

Child-Pugh B cirrhosis OR: 42.48 (95%CI: 4.41, 409.53)

Child-Pugh C cirrhosis OR: 69.30 (95%CI: 2.83, 1694.50) ^[91]

Viral hepatitis

The risk of severe COVID-19 is higher [RR: 1.68 (95%CI: 1.26, 2.22)]^[109]; however, another meta-analysis showed no association between viral hepatitis and poorer outcomes [pooled OR = 1.29 (95%CI: 0.36, 4.63)]^[90].

Cirrhosis

Cirrhotic patients experienced more severe disease (pooled OR = 3.09; 95%CI, 1.95–4.89)^[90].

Severity of cirrhosis associates with COVID-19 severity, as follows:

Child-Pugh A cirrhosis ⁶ OR: 1.90 (95%CI: 1.03, 3.52)

Child-Pugh B cirrhosis OR: 4.14 (95%CI: 2.4, 7.65)

Child-Pugh C cirrhosis OR: 9.32 (95%CI: 4.80, 18.08)^[110]

Liver transplant

No significant difference in mortality rates between LT and non-LT participants [OR: 0.8 (95%CI: 0.6, 1.08)].

The time between the transplantation and COVID-19 did not affect the mortality rate [OR: 1.5 (95%CI: 0.63, 3.56)].

Severe COVID-19 infection was observed in 23% of the participants with LT^[111].

NAFLD

NAFLD was associated with more severe COVID-19 [AOR: 2.60 (95%CI:2.24, 3.02)], more ICU admission ¹² [AOR: 1.66 (95%CI:1.26, 2.20)], but not higher mortality rates [AOR: 1.01 (95%CI:0.65, 1.58)]^[112].

MAFLD

¹ MAFLD increased the risk of severe COVID-19 (OR: 1.80, 95%CI: 1.53-2.13).

No association was found between the presence of MAFLD and the occurrence of COVID-19 death^[113].

Pregnancy

29.7% of pregnant patients with COVID-19 had liver injury

Liver injury can predispose pregnant females to experience more severe COVID-19; however, their neonates do not have worsen prognosis^[114].

AIH: Autoimmune hepatitis; AOR: Adjusted odds ratio; CLD: Chronic liver disease; ICU: Intensive care unit; LT: Liver transplant; MAFLD: Metabolic associated fatty liver

disease; MMF: Mycophenolate mofetil; NAFLD: Non-alcoholic fatty liver disease; OR: Odds ratio; RR: Relative risk.

Liver cirrhosis

COVID-19 is one of the main contributors to the exacerbation of preexisting liver cirrhosis^[115]. It is found that liver cirrhosis decompensation occurs in nearly half of the cirrhotic patients with COVID-19, one-fifth of whom might not develop any pulmonary manifestations^[110]. Therefore, physicians should be advised to consider COVID-19 in patients with cirrhosis exacerbation, even in the absence of respiratory symptoms. Because of cirrhosis-associated immune dysfunction, patients with decompensated liver cirrhosis are more susceptible to COVID-19^[116, 117]. The mortality rate in COVID-19 patients with decompensated liver cirrhosis was shown to be about 50%^[118]. The main predictor of mortality in cirrhotic patients with COVID-19 is the severity of underlying cirrhosis^[110]. Child-Pugh C cirrhosis has the highest odds for mortality among patients with CLD [OR=9.32 (95%CI: 4.80, 18.08)], while the odds ratio for Child-Pugh A was 1.90 (95%CI: 1.03, 3.52). Other predictors of mortality were higher age and concurrent alcoholic liver disease. One study reported that mortality, ventilation support, hospitalization, and ICU admission rates were significantly higher in patients with higher MELD scores, especially a score above ten^[119]. However, whether COVID-19 can worsen the outcomes in hospitalized patients with cirrhosis remains controversial. While some reports demonstrate that COVID-19 can elevate mortality rates in cirrhotic patients^[115, 120, 121], other studies found that COVID-19 did not significantly increase mortality in these patients^[122, 123]. Monitoring liver function tests, early detection of liver complications caused by a coronavirus, and broad-spectrum antibiotic therapy in case of secondary bacterial infection are highly recommended for successful management^[116].

The humoral response to COVID-19 vaccines is 94% in patients with CLD or cirrhosis. The mRNA vaccines are more efficacious than inactivated vaccines in these patients^[124].

Liver transplant

The success rate of transplantation is associated closely with the postoperative immunosuppression treatment to prevent organ rejection^[125]. Since the emergence of the pandemic, there has been a debate on the use and dosing of immunosuppressive drugs for these patients, as they act like a double-edged sword^[126]. While they can profoundly decrease the chance of organ rejection, severe immunosuppression can theoretically lead to uncontrolled viral replication and severe COVID-19^[127, 128]. MMF and calcineurin inhibitors, including tacrolimus are among the main immunosuppressive drugs used in LT patients^[129, 130]. MMF inhibits the proliferation of lymphocytes and suppresses cell-mediated immunity and antibody formation^[131]. LT patients who were previously treated with MMF have a higher risk of experiencing severe COVID-19 infection, especially those who have received doses more than 1000 mg/day^[131]. They also suggested a reduction in the dose of MMF or temporary conversion to other immunosuppressive drugs, including tacrolimus in LT patients^[131]. On the other hand, a meta-analysis found that the continued administration of certain immunosuppressive drugs during COVID-19 resulted in a lower probability of severe disease^[132]. Among the immunosuppressive drugs, the mammalian target of rapamycin inhibitor (mTORi) was the most effective in preventing severe disease, followed by calcineurin inhibitors, steroids, and antimetabolites.

Further studies, including a meta-analysis, indicated that the rate of severe COVID-19 and death was not higher in LT patients^[111]. Most deaths due to COVID-19 were associated with the cytokine storm and inflammatory process, not the result of direct viral replication^[133]. Therefore, not only is immunosuppression not harmful, but also it could prevent cytokine storm and reduce mortality. Guarino *et al*^[134] demonstrated that LT patients were more likely to become symptomatic; however, they did not exhibit more severe disease and death due to COVID-19. They did not reduce the dose of immunosuppressive drugs unless in severe and critical patients. This heterogeneity among the results can be attributed to the baseline characteristics of the patients, including the presence of other comorbidities, mean age, time from the transplant to COVID-19, and immunosuppressive drug. The strengths of the associations of these

factors were as follows: (a) Age > 70 [Hazard ratio (HR): 4.16 (95%CI: 1.78, 9.73)], (b) Tacrolimus use [HR: 0.55 (95%CI: 0.31, 0.99)], (c) ³diabetes [HR: 1.95 (95%CI: 1.06, 3.58)] (d) chronic kidney disease [HR: 1.97 (95%CI: 1.05, 3.67)], and (e) time between transplantation and COVID-19 [HR: 0.55(95%CI: 0.31, 0.99)]^[135, 136]. Therefore, we suggest that physicians assess the risk of severe disease in LT patients by considering age, comorbidities, and the time between the transplant and COVID-19. It is not necessary to modify the immunosuppressive drugs for all the patients; they can be closely monitored for the occurrence of risk factors and manifestations of severe disease and, if present, reducing the dose or changing the drugs can be applied. Besides, tacrolimus-based or mTORi-based immunosuppressive regimens have been proven to be safer with more favorable outcomes^[132, 137].

In addition, the response to COVID-19 vaccination is another important challenge in immunosuppressed patients. It is found that discontinuation or dose reduction of MMF optimizes the COVID-19 vaccination response in LT patients^[138, 139]. Moreover, it is necessary to consider booster shots in immunosuppressed patients who do not demonstrate the appropriate response to vaccinations^[140]. On the other hand, pre-exposure prophylaxis with tixagevimab/cilgavima can be beneficial in LT patients with severe immunosuppression who did not respond adequately to COVID-19 vaccination or COVID-19 vaccine contraindication^[141]. The humoral response to COVID-19 vaccines is 66% for patients with LT^[124]. Luo *et al*^[124] also revealed that the worse humoral response to COVID-19 vaccinations in LT patients was observed in patients with a history of using ⁴MMF [OR: 3.27 (95%CI: 1.45, 7.41)], diabetes [OR: 2.75 (95%CI: 1.48, 5.09)], and the use of > ² immunosuppressive drugs [OR: 3.13 (95%CI: 1.22, 7.99)].

Transplant candidates waiting ^{for} a donor are also considered high-risk due to their underlying liver disease. COVID-19 can complicate the LT process as an affected patient cannot undergo transplant surgery until declared recovered from COVID-19. It is suggested that the transplant should be performed with one negative COVID-19 RT-PCR test 24 h prior to the transplantation^[142]. It was found that COVID-19 infection before liver transplantation in patients with high MELD scores was not associated with

a higher mortality rate^[143]. As a result, postponing the surgery to a later time than what is suggested above is not recommended.

¹⁰ Nonalcoholic fatty liver disease

NAFLD is a liver manifestation of metabolic syndrome and is the most common CLD all over the world, affecting 30-40% of the world population^[144, 145]. The spectrum of NAFLD ranges from hepatocellular steatosis to advanced liver cirrhosis^[146]. There was a great heterogeneity across different studies which assessed the severity outcomes of COVID-19 in patients with NAFLD^[147-150]. Two meta-analyses suggested a more severe disease course and higher rates of ICU admission in NAFLD patients^[90, 112].

MAFLD is a more recent term to describe fatty liver disease in the context of metabolic syndrome^[145]. It is considered a better reflection of the disease pathogenesis and can contribute to a more appropriate disease classification and management. NAFLD patients were diagnosed and included in the studies mainly based on their imaging (computed tomography or sonography) findings; however, metabolic risk abnormalities should be considered beside the imaging findings of hepatic steatosis to label a patient as MAFLD^[151]. The existence of MAFLD can lead to the release of more inflammatory cytokines and worsens the inflammatory process in COVID-19 infected patients^[152]. Gao *et al*^[153] found that the elevated level of IL-6 was associated with poorer COVID-19 outcomes in MAFLD patients. Leptin dysregulation in metabolic syndrome and obesity can be responsible for the more prominent cytokine storm observed in these conditions^[154]. Therefore, it seems that metabolic syndrome features which are incorporated in the definition of MAFLD are the determinants of the disease severity in patients with fatty liver. This also clarifies the inconsistency of the results about disease severity in NAFLD patients with COVID-19, but a more consistent result for MAFLD that we described above.

Another predictor of disease severity is the degree of NAFLD or MAFLD and liver fibrosis. Targher *et al*^[149] found that MAFLD patients with intermediate to high fibrosis-4 (FIB-4) scores had poorer COVID-19 outcomes [OR for intermediate FIB-4= 4.32 (95% CI: 1.94, 9.59), OR for high FIB-4= 5.73 (95% CI: 1.84, 17.9)]. Another study

found that the increase in various liver fibrosis scores, including FIB-4, aspartate aminotransferase to platelet ratio index (APRI), NAFLD fibrosis score (NFS), and Forns scores was associated with worse COVID-19 outcomes and, as a result, can be used as prognostic factors^[155]. However, their accuracy in identifying liver fibrosis is not acceptable in young individuals and both extremes of body mass index^[156, 157].

Pregnancy

The presence of liver involvement can partially impact COVID-19 prognosis in pregnant patients. It is shown that the duration of admission in COVID-19 pregnant females is more prolonged in those with liver involvement^[158]. Moreover, pregnant females with liver injury are at higher risk of developing severe disease^[114]. Nevertheless, their neonates do not have an excessive risk for worsening prognosis.

The prevalence of COVID-19-related liver injury in pregnant women is nearly 30%, which is relatively similar to the general population^[114]. The first step in managing a pregnant patient who presents with COVID-19 and liver injury is to identify the cause of liver damage and exclude obstetric diagnoses. COVID-19-related liver involvement can be mistaken for preeclampsia^[159], HELLP syndrome^[160], acute fatty liver of pregnancy^[159], and intrahepatic cholestasis^[161]. All these conditions warrant early diagnosis and require certain urgent management. Therefore, it is highly recommended to monitor liver function tests in pregnant females^[114].

Myalgia is one of the most common presentations of COVID-19, which is usually managed with acetaminophen plus non-steroidal anti-inflammatory drugs (NSAID)^[162]. As the use of high-dose NSAID is not recommended during pregnancy, especially during the third trimester, higher doses of acetaminophen might be prescribed to control the pain, which might exacerbate the underlying liver disease. Therefore, physicians should calculate the safe dose of acetaminophen to prevent the exacerbation of underlying liver disease^[163].

Infants and children

Severe COVID-19 disease in adults is linked to dysfunctional cellular immunity and unchecked inflammatory cytokines production^[164]. The unaffected immunosuppressive

and cellular elements of the immune system in children can result in a less aggressive course of COVID-19. This milder course of COVID-19 can explain the lower rate of elevated AST and ALT in children (6%-22%)^[165, 166], compared to adults (14%-53%)^[167]. The most common hepatic presentation of COVID-19 is the elevation of liver enzymes. Elevated ALT is usually seen in older male children^[168]. Supportive treatment is generally considered for managing COVID-19-affected children with liver involvement. In addition to COVID-19-related liver injury, pediatricians should be aware of the management of COVID-19 in children with pre-existing liver disease. It was revealed that the severity of COVID-19 was not higher in children with CLD^[169]. Therefore, children with stable CLD can be managed virtually with a well-organized telemedicine system. Similar to adults, in children with autoimmune liver disease or LT, who are receiving immunosuppressive drugs, it is not recommended to decrease the dose of drugs in mild cases, as it can increase the chance of organ rejection^[164].

Neonates can be affected by COVID-19 *via* three routes: antenatal, peripartum, and postnatal. Liver involvement in neonates is mainly characterized by elevated liver enzymes. In these cases, the first step is to exclude other causes of abnormal liver function tests^[170]. Remdesivir should be administered in neonates with COVID-19 with great caution and only in severe cases as it can worsen liver injury in COVID-19-infected neonates^[171].

EPIDEMIOLOGICAL ASPECTS OF LIVER DISEASE DURING THE COVID-19 PANDEMIC

COVID-19 can cause liver injury *via* different mechanisms discussed above. In addition to these mechanisms, the COVID-19 pandemic contributed to some changes in the pattern and epidemiology of some of the hepatic diseases.

Alcoholic liver disease

The amount of alcohol consumption and prevalence of alcoholic liver disease have risen during the COVID-19 pandemic. Several reports from different countries worldwide demonstrated a significant rise in the amount of alcohol use during the pandemic,

including the United States^[172], China^[173], and England^[174]. It is postulated that this increase resulted from financial problems, job loss, and mental distress during the pandemic^[175-177]. Besides, the psychological impacts of the loss of beloved ones, social isolation, lockdown, and other mitigation strategies that were implemented to control the disease have resulted in a greater level of mental distress and, as a result, aggravated alcohol use even more^[178-180]. Therefore, it was expected to observe higher rates of alcoholic liver diseases and their burden. Numerous reports from across the globe provided data regarding the increased burden, hospitalization, and mortality due to excessive alcohol consumption during the pandemic. A study from Canada found that the rates of monthly hospitalization due to alcoholic hepatitis increased from 11.6 before March 2020 to 22.1 cases per 10000 amid the pandemic, which indicates a nearly two-fold increase in the number of cases^[181]. A similar increase rate was also observed in another study from England^[182]. Two reports from the United States suggested a nearly 50% increase in the case admission due to alcoholic hepatitis during the pandemic^[183, 184]. In concordance with the increase in case hospitalization, we also observed a 20% rise in mortality rates due to alcoholic hepatitis^[185]. Females and younger individuals are more likely to experience these increasing trends in hospitalization and mortality rates due to alcoholic liver disease^[184, 185]. Several strategies can be implemented to mitigate the detrimental effects of the COVID-19 pandemic on patients with alcohol use disorders. Developing a well-organized telemedicine system can help better identification of high-risk persons and provide consultation, health-related suggestions, and surveillance^[180]. The screening programs can also be used for earlier identification of at-risk groups for alcohol use disorder.

11 Alcohol Use Disorders Identification Test – Consumption (AUDIT-C) and Single Alcohol Screening Question (SASQ) are two recommended screening tools for assessing alcohol use disorder and are suggested to be used for all persons over 18 during primary care evaluation^[186, 187].

Hepatitis B virus

In addition to alcoholic liver disease, HBV infection is another hepatic disease which is affected by the COVID-19 pandemic. Implementation of the strategies to mitigate the spread of the pandemic, including the lockdown, resulted in more difficult access to the healthcare facilities and, thus, reduced the willingness of many patients to seek medical services^[188]. As a result, the number of HBV tests was reduced, and HBV diagnosis and treatment were impacted negatively amid the pandemic^[189]. In addition, there are reports which indicate that the failure of the screening programs lowers the number of HBV vaccination and aggravates the preexisting health inequalities during the pandemic^[189, 190]. All these can contribute to a notable rise in the number of HBV cases. Similar to what we proposed to tackle the burden associated with the alcoholic liver disease during the pandemic, telemedicine and remote screening programs can be useful to resolve the pandemic-related disruptions in HBV infection management. Also, integrating the messaging system and contact tracing into the screening programs is suggested to increase the efficacy of screening; however, their effectiveness is yet to be determined by future studies^[191].

CONCLUSION

Liver injury is a relatively common manifestation of COVID-19, mostly presenting with elevated liver enzymes. Different mechanisms for COVID-19-induced liver injury, including direct viral effect, cytokine storm, hepatic congestion, hypoxia, and reperfusion injury are proposed. Most cases of liver injury are mild and only require supportive treatment; however, there are some underlying liver diseases which might require special considerations. NAFLD and MAFLD were associated with the highest OR for severe COVID-19. Also, more severe disease is expected in patients with liver cirrhosis, especially cases with more advanced liver fibrosis. Despite the immunocompromised status in LT and AIH patients, they are not at a significantly higher risk of severe disease, and there is no need to empirically reduce or change the immunosuppressive drugs.

ACKNOWLEDGEMENTS

The authors would like to thank the Research Consultation Center (RCC) of Shiraz University of Medical Science for their assistance in revising the manuscript.

6%

SIMILARITY INDEX

PRIMARY SOURCES

- | | | |
|----------|---|-----------------|
| 1 | www.ncbi.nlm.nih.gov
<small>Internet</small> | 83 words — 1% |
| <hr/> | | |
| 2 | www.wjgnet.com
<small>Internet</small> | 52 words — 1% |
| <hr/> | | |
| 3 | covid19dataportal.es
<small>Internet</small> | 35 words — < 1% |
| <hr/> | | |
| 4 | De Luo, Xinpei Chen, Juan Du, Bingjie Mei et al. "Immunogenicity of COVID - 19 vaccines in chronic liver disease patients and liver transplant recipients: a systematic review and meta - analysis", Liver International, 2022
<small>Crossref</small> | 32 words — < 1% |
| <hr/> | | |
| 5 | Thomas Marjot, Gustav Buescher, Marcial Sebode, Eleanor Barnes et al. "SARS-CoV-2 infection in patients with autoimmune hepatitis", Journal of Hepatology, 2021
<small>Crossref</small> | 32 words — < 1% |
| <hr/> | | |
| 6 | detectdiabetes.com
<small>Internet</small> | 29 words — < 1% |
| <hr/> | | |
| 7 | journals.squ.edu.om
<small>Internet</small> | 22 words — < 1% |

8	radiopaedia.org Internet	19 words — < 1%
9	pubmed.ncbi.nlm.nih.gov Internet	18 words — < 1%
10	www.researchgate.net Internet	16 words — < 1%
11	access.oakstone.com Internet	15 words — < 1%
12	"Abstracts from the 30th Annual Meeting of the Society of General Internal Medicine", Journal of General Internal Medicine, 2007 Crossref	14 words — < 1%
13	www.yumpu.com Internet	14 words — < 1%
14	Hend Ibrahim Shousha, Ahmed Ramadan, Rania Lithy, Mohamed El-Kassas. "Patterns of liver profile disturbance in patients with COVID-19", World Journal of Clinical Cases, 2022 Crossref	13 words — < 1%
15	Nikita Patil, Pankush Kalgotra, Suneha Sundaram, Stephanie Melquist, Sravanthi Parasa, Madhav Desai, Prateek Sharma. "Factors associated with poor outcomes among COVID-19 patients with gastrointestinal symptoms", Gastro Hep Advances, 2022 Crossref	13 words — < 1%
16	eurjmedres.biomedcentral.com Internet	13 words — < 1%
17	journals.lww.com	

13 words — < 1%

-
- 18 Matthew J. McConnell, Reiichiro Kondo, Nao Kawaguchi, Yasuko Iwakiri. "Covid - 19 and Liver Injury: Role of Inflammatory Endotheliopathy, Platelet Dysfunction, and Thrombosis", Hepatology Communications, 2021
Crossref

12 words — < 1%

-
- 19 academic.oup.com
Internet

12 words — < 1%

-
- 20 www.intechopen.com
Internet

12 words — < 1%

-
- 21 www.nature.com
Internet

12 words — < 1%

EXCLUDE QUOTES ON

EXCLUDE BIBLIOGRAPHY ON

EXCLUDE SOURCES

< 12 WORDS

EXCLUDE MATCHES

< 12 WORDS